Shanghai Innogen Pharmaceutical Technology Co., Ltd. is a science-driven biotechnology company dedicated to the research and development of innovative and affordable medicines for diabetes and other metabolic disease patients. Innogen’s pipeline in metabolic disease, including Type 1 & 2 diabetes, obesity and NASH, is independently developed and has global market rights.
Supaglutide, the company’s first pipeline product, Efsubaglutide Alfa (previously named as Supaglutide, with trade name: DiabegoneTM ), was approved by the NMPA in January, 2025. It is the first humanized long-acting GLP-1 drug that originated from China, which will benefit more diabetes patients. Other indications for Efsubaglutide Alfa such as obesity and MASH are also under development to address the large unmet therapeutic needs in these disease areas.
Supaglutide, the company’s first pipeline product, Efsubaglutide Alfa (previously named as Supaglutide, with trade name: DiabegoneTM ), was approved by the NMPA in January, 2025. It is the first humanized long-acting GLP-1 drug that originated from China, which will benefit more diabetes patients. Other indications for Efsubaglutide Alfa such as obesity and MASH are also under development to address the large unmet therapeutic needs in these disease areas.
Location: China, Shanghai
Employees: 11-50
Investors 3
| Date | Name | Website |
| 18.05.2025 | Centurium ... | centurium.... |
| - | HONGTAI Ap... | apluscap.c... |
| 02.11.2025 | Cowin Capi... | cowincapit... |